Premier Asset Managment LLC cut its stake in Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) by 4.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 81,085 shares of the biopharmaceutical company’s stock after selling 3,335 shares during the period. Alexion Pharmaceuticals accounts for 2.5% of Premier Asset Managment LLC’s investment portfolio, making the stock its 21st largest position. Premier Asset Managment LLC’s holdings in Alexion Pharmaceuticals were worth $9,936,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Eqis Capital Management Inc. raised its stake in Alexion Pharmaceuticals by 4.3% in the second quarter. Eqis Capital Management Inc. now owns 9,727 shares of the biopharmaceutical company’s stock valued at $1,136,000 after buying an additional 400 shares during the period. MAI Capital Management raised its stake in Alexion Pharmaceuticals by 46.5% in the second quarter. MAI Capital Management now owns 4,281 shares of the biopharmaceutical company’s stock valued at $500,000 after buying an additional 1,358 shares during the period. Capstone Asset Management Co. raised its stake in Alexion Pharmaceuticals by 4.7% in the second quarter. Capstone Asset Management Co. now owns 24,573 shares of the biopharmaceutical company’s stock valued at $2,869,000 after buying an additional 1,095 shares during the period. Gateway Investment Advisers LLC raised its stake in Alexion Pharmaceuticals by 14.2% in the second quarter. Gateway Investment Advisers LLC now owns 184,840 shares of the biopharmaceutical company’s stock valued at $21,582,000 after buying an additional 23,032 shares during the period. Finally, Webster Bank N. A. raised its stake in Alexion Pharmaceuticals by 40.0% in the second quarter. Webster Bank N. A. now owns 7,000 shares of the biopharmaceutical company’s stock valued at $817,000 after buying an additional 2,000 shares during the period. Hedge funds and other institutional investors own 94.85% of the company’s stock.

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) traded up 0.46% during trading on Monday, hitting $119.38. 1,880,453 shares of the company traded hands. The firm has a market cap of $26.76 billion, a price-to-earnings ratio of 72.79 and a beta of 1.45. The company’s 50-day moving average is $122.72 and its 200 day moving average is $129.05. Alexion Pharmaceuticals Inc. has a 52-week low of $110.56 and a 52-week high of $193.45.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, October 27th. The biopharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.04 by $0.19. The business had revenue of $799 million for the quarter, compared to analyst estimates of $787.07 million. Alexion Pharmaceuticals had a net margin of 12.46% and a return on equity of 10.58%. The company’s revenue for the quarter was up 19.9% compared to the same quarter last year. During the same period last year, the firm posted $1.16 earnings per share. On average, equities analysts anticipate that Alexion Pharmaceuticals Inc. will post $4.64 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Premier Asset Managment LLC Has $9,936,000 Stake in Alexion Pharmaceuticals Inc. (ALXN)” was published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this piece on another domain, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece can be accessed at https://www.thecerbatgem.com/2016/11/28/premier-asset-managment-llc-has-9936000-stake-in-alexion-pharmaceuticals-inc-alxn.html.

A number of equities research analysts recently weighed in on the stock. Vetr lowered shares of Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $150.62 price objective for the company. in a report on Wednesday, August 3rd. Jefferies Group reiterated a “hold” rating on shares of Alexion Pharmaceuticals in a report on Tuesday, August 9th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $185.00 price objective on shares of Alexion Pharmaceuticals in a report on Tuesday, August 16th. Wedbush assumed coverage on shares of Alexion Pharmaceuticals in a report on Thursday, September 22nd. They set a “neutral” rating and a $132.00 price objective for the company. Finally, Zacks Investment Research lowered shares of Alexion Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Wednesday, November 2nd. One analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $173.36.

In related news, EVP Carsten Thiel sold 4,584 shares of Alexion Pharmaceuticals stock in a transaction on Friday, October 14th. The shares were sold at an average price of $120.28, for a total value of $551,363.52. Following the transaction, the executive vice president now directly owns 32,741 shares in the company, valued at approximately $3,938,087.48. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Leonard Bell sold 1,300 shares of Alexion Pharmaceuticals stock in a transaction on Monday, October 31st. The shares were sold at an average price of $135.28, for a total transaction of $175,864.00. Following the completion of the transaction, the director now owns 406,589 shares in the company, valued at $55,003,359.92. The disclosure for this sale can be found here. Insiders own 4.41% of the company’s stock.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

5 Day Chart for NASDAQ:ALXN

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.